FDA approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread, but that continues to grow despite treatment with hormone therapy. This is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer.
FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint
YOU MAY BE INTERESTED IN
President Joe Biden April 9 announced his FY2022 budgetary plans for ARPA-H—Advanced Research Projects Agency-Health—a federal entity designed to “deliver breakthroughs to find cures for cancer and other diseases.” In his initial White House budget proposal—dubbed skinny budget, or budget-lite—Biden is requesting $6.5 billion to fund ARPA-H. “The discretionary request calls for $6.5 billion to...
Today Dr. Roswell Park is remembered mostly as the founder of the world’s first cancer research institute, which still bears his name proudly to this day in Buffalo, NY, but his contributions to medicine extend much further.